PURPOSE: Ciprofloxacin can inhibit the cytochrome P450-mediated metabolism of theophylline, but the clinical relevance of this drug interaction is uncertain. We studied the risk of theophylline toxicity associated with the co-prescription of ciprofloxacin and theophylline. METHODS: This was a population-based, nested case-control study of a cohort of Ontario residents aged 66 years of age or older treated with theophylline between April 1, 1992 and March 31, 2009. Within this group, case patients were those hospitalized with theophylline toxicity. For each case, 50 age- and sex-matched control patients were identified from the same cohort. The odds ratio (OR) for the association between hospitalization for theophylline toxicity and receipt of ciprofloxacin in the 14 days preceding hospitalization was determined. RESULTS: Among the 77,251 elderly patients receiving therapy with theophylline, 180 eligible case patients hospitalized for theophylline toxicity and 9000 matched controls were identified. Following multivariable adjustment, a nearly twofold increase in the risk of theophylline toxicity following the receipt of ciprofloxacin was observed [adjusted OR 1.86, 95% confidence interval (CI) 1.18-2.93]. In contrast, there was no increased risk of theophylline toxicity within a group of patients receiving neutral comparator antibiotics (levofloxacin, trimethoprim-sulfamethoxazole or cefuroxime) (adjusted OR 0.78; 95% CI 0.38-1.62). CONCLUSION: Treatment with ciprofloxacin is associated with a significant increase in the risk of theophylline toxicity. When clinically appropriate, alternate antibiotics should be considered for elderly patients receiving theophylline.
PURPOSE:Ciprofloxacin can inhibit the cytochrome P450-mediated metabolism of theophylline, but the clinical relevance of this drug interaction is uncertain. We studied the risk of theophyllinetoxicity associated with the co-prescription of ciprofloxacin and theophylline. METHODS: This was a population-based, nested case-control study of a cohort of Ontario residents aged 66 years of age or older treated with theophylline between April 1, 1992 and March 31, 2009. Within this group, case patients were those hospitalized with theophyllinetoxicity. For each case, 50 age- and sex-matched control patients were identified from the same cohort. The odds ratio (OR) for the association between hospitalization for theophyllinetoxicity and receipt of ciprofloxacin in the 14 days preceding hospitalization was determined. RESULTS: Among the 77,251 elderly patients receiving therapy with theophylline, 180 eligible case patients hospitalized for theophyllinetoxicity and 9000 matched controls were identified. Following multivariable adjustment, a nearly twofold increase in the risk of theophyllinetoxicity following the receipt of ciprofloxacin was observed [adjusted OR 1.86, 95% confidence interval (CI) 1.18-2.93]. In contrast, there was no increased risk of theophyllinetoxicity within a group of patients receiving neutral comparator antibiotics (levofloxacin, trimethoprim-sulfamethoxazole or cefuroxime) (adjusted OR 0.78; 95% CI 0.38-1.62). CONCLUSION: Treatment with ciprofloxacin is associated with a significant increase in the risk of theophyllinetoxicity. When clinically appropriate, alternate antibiotics should be considered for elderly patients receiving theophylline.
Authors: Kazuhiro Ito; Sam Lim; Gaetano Caramori; Borja Cosio; K Fan Chung; Ian M Adcock; Peter J Barnes Journal: Proc Natl Acad Sci U S A Date: 2002-06-17 Impact factor: 11.205
Authors: David N Juurlink; Muhammad Mamdani; Alexander Kopp; Andreas Laupacis; Donald A Redelmeier Journal: JAMA Date: 2003-04-02 Impact factor: 56.272
Authors: Laura Y Park-Wyllie; David N Juurlink; Alexander Kopp; Baiju R Shah; Therese A Stukel; Carmine Stumpo; Linda Dresser; Donald E Low; Muhammad M Mamdani Journal: N Engl J Med Date: 2006-03-01 Impact factor: 91.245
Authors: G Mahr; F Sörgel; G R Granneman; M Kinzig; P Muth; K Patterson; U Fuhr; P Nickel; U Stephan Journal: Clin Pharmacokinet Date: 1992 Impact factor: 6.447
Authors: Joseph T Hanlon; Subashan Perera; Paul J Drinka; Christopher J Crnich; Steven J Schweon; Michele Klein-Fedyshin; Charles B Wessel; Stacey Saracco; Gulsum Anderson; Mary Mulligan; David A Nace Journal: J Am Geriatr Soc Date: 2018-12-24 Impact factor: 5.562
Authors: Johannes Fexer; Ewan Donnachie; Antonius Schneider; Stefan Wagenpfeil; Manfred Keller; Frank Hofmann; Michael Mehring Journal: Dtsch Arztebl Int Date: 2014-04-25 Impact factor: 5.594
Authors: Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede Journal: J Antimicrob Chemother Date: 2019-10-01 Impact factor: 5.790
Authors: Mina Tadrous; Diana Martins; Zhan Yao; Muhammad M Mamdani; David N Juurlink; Tara Gomes; Tony Antoniou Journal: PLoS One Date: 2016-09-23 Impact factor: 3.240